The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?

Figure 1

Antidiabetic insulin-dependent and insulin-independent effects of GLP-1 on metabolic tissues, which are potentiated by inhibition of dipeptidyl peptidase-4, thus improving the glycaemic, insulinemic, and lipidic profile and the progression of the disease.